Straits Times Index
3,277.80 -9.95 (-0.30%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,636.52 +351.98 (+2.04%) FTSE 100
8,122.51 +43.65 (+0.54%) Bitcoin USD
64,320.83 +351.69 (+0.55%) CMC Crypto 200
1,390.72 -5.82 (-0.42%)
BrainsWay Ltd. (BRSYF)
| Previous close | 2.4700 |
| Open | 2.4700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4700 - 2.4700 |
| 52-week range | 0.9000 - 2.9700 |
| Volume | |
| Avg. volume | 101 |
| Market cap | 83.999M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.40 |
GlobeNewswireBrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024
BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to dis
- GlobeNewswire
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
Company Announces 11th Recent System Installed in Israel, with More Expected this YearBURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS™ treatment in Israel. BrainsWay has steadily increased its presence in the country with 11 recent system installatio
- GlobeNewswire
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor SymptomsJERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a novel therapeutic approach for Park
